Key result
Atorvastatin significantly reduced thrombotic risk assessed by peak thrombin generation compared to control (85.09 vs 153.26 nmol) in diabetic patients without previous cardiovascular events, whereas aspirin had no effect.
Why the study?
Does aspirin or atorvastatin reduce thrombin generation in patients with type 2 diabetes without previous cardiovascular events?
Population
30 patients aged ≥50 years with type 2 diabetes mellitus diagnosed at least 1 year prior, no previous…
Comparison
2x2 factorial design: Aspirin 100 mg daily… vs No treatment (control group) for 8 to 10 weeks.
Design
RCT, Centrally randomized using a random allocation sequence generated by…
Follow-up
8 to 10 weeks
Authors
Loading...
Supports atorvastatin for thrombin reduction in diabetes primary prevention; challenges aspirin efficacy and extends statin pleiotropy data.
RCT (n=30)
Open-label, blinded to events evaluation (PROBE)
Random allocation sequence generated by computer
Yes
Does aspirin or atorvastatin reduce thrombin generation in patients with type 2 diabetes without previous cardiovascular events?
Absolute Event Rate: 85.09% vs 153.26%
p-value: p=0.018
In patients with type 2 diabetes without previous cardiovascular events, atorvastatin but not aspirin significantly reduced thrombotic risk as assessed by thrombin generation.
Macchia et al. (2012) conducted an RCT in Type 2 diabetes mellitus without previous cardiovascular events (n=30). Atorvastatin vs. No atorvastatin was evaluated on Peak thrombin generation (PTG) with saline as agonist at the end of follow-up (p=0.018). Atorvastatin significantly reduced thrombotic risk assessed by peak thrombin generation compared to control (85.09 vs 153.26 nmol) in diabetic patients without previous cardiovascular events, whereas aspirin had no effect.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: